people experience TBI globally1
of TBIs are of mild severity2
people experience TBI globally1
of TBIs are of mild severity2
The NanoDx™ System offers an objective alternative for assessing patients suspected of mild or moderate TBI at the point of care—quickly and cost-effectively*. Using our patented nano biosensor technology, the NanoDx™ Tbit™ test delivers accurate measurement of two biomarkers indicative of brain injury.
Calcium-binding peptide that increases from glial activation and/or death following TBI.7
Glial fibrillary acidic protein is a type III intermediate filament protein that increases following TBI.8
Definitive assessment helps avoid misdiagnosed patients.
Accelerate clinical decisions with lab-accurate tests in 2 minutes.
In a pre-clinical feasibility study (n=100) test demonstrated 100% sensitivity and 0 false negatives.
Delivers lab-accurate results with just a fingerstick of blood.